“ licensed know - how ” means any unpatentable or unpatented developments, proprietary knowledge, ideas, specifications, prototypes, drawings, know - how, formulas, information, data, methods, processes, tools, designs, testing programs, expertise, concepts or techniques, and similar knowledge not known by licensee prior to licensor disclosing such knowledge to licensee, solely to the extent that they are ( a ) pertinent to the licensed patents, ( b ) not subject to the exclusive rights of any third parties or research sponsor restrictions, ( c ) ( i ) in existence, and known to the inventor or members of his laboratory ( ies ), as of the effective date or ( ii ) generated by or on behalf licensor ( solely or jointly with others ) during the term through the exercise of licensor ’ s retained rights under section 2. 4. 1, including non - clinical and clinical data ( including clinical data generated in connection with the phase i clinical trial for tnbc ), and ( d ) applicable primarily within the fields, further described in appendix a. milestone sublicense rate * * * * * * * * * * * * * * * * * * * * * * * * year mar * * * * * * * * * * * * * * * * * * * * * * * * amount milestone activity * * * * * * * * * * * * * * * * * * amount milestone activity * * * * * * * * * * * * * * * * * * milestone milestone date * * * * * * * * * * * * * * * * * * * * * * * * milestone milestone date * * * * * * * * * * * * * * * * * * * * * * * * licensee / sublicensee : agreement effective date : period reported : product name or catalog number description activity type ( external sales / internal sales ) country sold to : number of units sold total quarterly gross sales less allowable deductions net sales royalty rate other income ( including sublicensing revenue ) total due ( us, canada, japan, etc. ) ( note ccf sales ) total : total : $ - total royalties due $ - prior quarterly payments : $ - minimum annual $ - $ - cumulative net sales : licensee / sublicensee : agreement effective date : period reported :